Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Buse JB, Bain SC, Mann JFE, Nauck MA, et al. Diabetes Care 2020;43:1546-1552.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Buse JB, Bain SC, Mann JFE, Nauck MA, et al. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care 2020;43:1546-1552.
PMID: 32366578